Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
José‐Tomás Navarro(Universitat Autònoma de Barcelona), Evarist Feliú(Universitat Autònoma de Barcelona), Albert Oriol(Institut Català d'Oncologia), Miquel Pujol(Instituto de Salud Carlos III), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Josep‐María Ribera(Universitat Autònoma de Barcelona), F Millá, José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor)
PubMed
November 1, 1998
Cited by 59
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719